Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 23:00 local time 16th of January 2021

Situation Report No. 218 - State of Kuwait

17th of January, 2021

World Health Organization

	Glo	bal	Eastern Mediterranean Region		
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths	
Total	92,506,811	2,001,773	5,309,701	127,388	
New	2,171,803 in 3 days	47,437 in 3 days	87,235 in 3 days	1,346 in 3 days	

State of Kuwait

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	157,399	150,678	947	5,774	48	1,389,294
New	1,525 in 3 days	869 in 3 days	1 in 3 days	-	-	29,873 in 3 days

HIGHLIGHTS

• Registration for Covid-19 vaccination has reached 250,000 while more than 20,000 have received the first dose. Hall no 6 at the International Fairgrounds is used to provide COVID-19 vaccination to increase daily vaccination capacity.

- A certificate of vaccination will be given upon receiving the 2nd dose of the vaccine.
 The decision of airlines obligation to pay for PCR tests for arrivals is postponed until further notice.
- Gulf Health Council published the gulf guideline for the diagnosis and treatment of COVID-19 guide, the second version (1.1), see link.
- Unicef publishes a "Vaccine Misinformation Management Field Guide", see link.
- WHO provides a practical guide for analysing and using routine data to monitor the effects of COVID-19 on essential health services, see link.
- WHO published a background document to the WHO Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine under Emergency Use Listing, see link.

IMPORTANT LINKS

- MoH update of COVID-19: https://corona.e.gov.kw/en/
- MoH's link to register for the vaccine:
- https://cov19vaccine.moh.gov.kw/SPCMS/CVD_19_Vaccine_RegistrationAr.aspx
- WHO's COVID-19 weekly situation reports:
- https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports • WHO's COVID-19 dashboard: https://covid19.who.int/
- GCC guideline for the diagnosis and treatment of COVID-19 guide: http://www.ghc.sa/ar-
- sa/Documents/GCC-Screening-and-Diagnostic-Guideline.pdf
- Unicef's Vaccine Misinformation Management Field Guide:
- https://www.unicef.org/mena/reports/vaccine-misinformation-management-field-guide • Analysing and using routine data to monitor the effects of COVID-19 on essential health services: https://www.who.int/publications/i/item/WHO-2019-nCoV-
- essential health services-monitoring-2021.1
- Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19:

https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19

IMPORTANT DEFINITIONS

Who can take the Pfizer-BioNTech COVID-19 vaccine?

According to SAGE (WHO's Strategic Group of Experts on Immunization), the Pfizer-BioNTech COVID-19 mRNA vaccine is safe and effective. Nevertheless, there are specific populations for whom vaccination is not recommended for a variety of reasons. These populations currently include people with a history of severe allergics, (particularly it is contraindicated for People with a history of severe allergic reaction to any component of the vaccine), most pregnant women (except for those with unavoidable high risk of exposure such as health workers), international travellers who are not part of a prioritized group (due to limited supplies of the vaccine at present), and children under 16 (due to lack of data). Further studies are needed for immune-compromized persons. The priority is to start vaccinating health workers at high risk of exposure, followed by older adults, before immunizing the rest of the population. For more details see the link above.

IMPORTANT CONTACTS

• The National Focal Person is Dr Buthaina AlMudhaf, Assistant Undersecretary, Ministry of Health, email: AlMudhaf@gmail.com





